Literature DB >> 30256723

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.

Caroline K Kramer1,2,3, Bernard Zinman1,2,3.   

Abstract

Clinical studies evaluating the cardiovascular safety/impact of sodium-glucose cotransporter-2 (SGLT-2) inhibitors demonstrated a reduction in major adverse cardiovascular events driven primarily by a reduced cardiovascular mortality in individuals with type 2 diabetes and previous cardiovascular disease. These somewhat unexpected results are coupled with SGLT-2 inhibitors' known acute effect of improvement in glycemia, reduction in blood pressure, and weight loss. In this review, we summarize the mechanism of action of SGLT-2 inhibitors, the metabolic effects of this class of medication, and the remarkable results of cardiovascular safety trials. In addition, we discuss adverse effects associated with these medications and the current recommendations for the use of these agents in the management of diabetes.

Entities:  

Keywords:  SGLT-2; T2DM; cardiovascular disease; glucose lowering; sodium–glucose cotransporter–2 inhibitors; type 2 diabetes mellitus

Year:  2018        PMID： 30256723     DOI： 10.1146/annurev-med-042017-094221

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN： 0066-4219            Impact factor:   13.739


  14 in total

Review 1.  Basic Mechanisms of Diabetic Heart Disease.

Authors:  Rebecca H Ritchie; E Dale Abel
Journal:  Circ Res       Date:  2020-05-21       Impact factor: 17.367

Review 2.  Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D.

Authors:  Olga González-Albarrán; Cristóbal Morales; Manuel Pérez-Maraver; José Juan Aparicio-Sánchez; Rafael Simó
Journal:  Diabetes Ther       Date:  2022-06-15       Impact factor: 3.595

3.  Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.

Authors:  Yake Lou; Ying Yu; Junchao Duan; Sining Bi; Khaing Nyein Chan Swe; Ziwei Xi; Yanan Gao; Yujie Zhou; Xiaomin Nie; Wei Liu
Journal:  Ther Adv Chronic Dis       Date:  2020-09-26       Impact factor: 5.091

4.  Gene knockout of the Na+-glucose cotransporter SGLT2 in a murine model of acute kidney injury induced by ischemia-reperfusion.

Authors:  Josselin Nespoux; Rohit Patel; Haiyan Zhang; Winnie Huang; Brent Freeman; Paul W Sanders; Young Chul Kim; Volker Vallon
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-02

5.  Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients.

Authors:  Kazushi Uneda; Yuki Kawai; Takayuki Yamada; Sho Kinguchi; Kengo Azushima; Tomohiko Kanaoka; Yoshiyuki Toya; Hiromichi Wakui; Kouichi Tamura
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

6.  Class effect for SGLT-2 inhibitors: a tale of 9 drugs.

Authors:  Dario Giugliano; Katherine Esposito
Journal:  Cardiovasc Diabetol       Date:  2019-07-23       Impact factor: 9.951

Review 7.  Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.

Authors:  Dario Giugliano; Miriam Longo; Lorenzo Scappaticcio; Paola Caruso; Katherine Esposito
Journal:  Cardiovasc Diabetol       Date:  2021-01-11       Impact factor: 9.951

Review 8.  Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.

Authors:  Michele Provenzano; Maria Chiara Pelle; Isabella Zaffina; Bruno Tassone; Roberta Pujia; Marco Ricchio; Raffaele Serra; Angela Sciacqua; Ashour Michael; Michele Andreucci; Franco Arturi
Journal:  Front Med (Lausanne)       Date:  2021-06-04

9.  Incidence of idiopathic cardiomyopathy in patients with type 2 diabetes in Taiwan: age, sex, and urbanization status-stratified analysis.

Authors:  Hua-Fen Chen; Ya-Hui Chang; Hsien-Jung Lo; Muhammad Atoillah Isfandiari; Santi Martini; Wen-Hsuan Hou; Chung-Yi Li
Journal:  Cardiovasc Diabetol       Date:  2020-10-14       Impact factor: 9.951

10.  Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study.

Authors:  Christopher Sainsbury; Jingya Wang; Krishna Gokhale; Dionisio Acosta-Mena; Samir Dhalla; Nathan Byne; Joht Singh Chandan; Astha Anand; Jennifer Cooper; Kelvin Okoth; Anuradhaa Subramanian; Mansoor N Bangash; Thomas Taverner; Wasim Hanif; Sandip Ghosh; Parth Narendran; Kar K Cheng; Tom Marshall; Georgios Gkoutos; Konstantinos Toulis; Neil Thomas; Abd Tahrani; Nicola J Adderley; Shamil Haroon; Krishnarajah Nirantharakumar
Journal:  Diabetes Obes Metab       Date:  2020-10-19       Impact factor: 6.408
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.